Exclusive: OpenAI has acquired Orchestra Bio

OpenAI has acquired Orchestra Bio, a startup creating AI agents to assist pharmaceutical companies in managing drug development. This move allows OpenAI to expand into science, competing with Anthropic. The technology and team will be integrated into Rosalind, OpenAI's suite of AI models for life sciences researchers. Orchestra's platform enables scientists to delegate critical tasks, including monitoring studies, tracking development timelines, and identifying potential delays, to AI agents to streamline the pharmaceutical research process.